In this episode of The Midweek Takeaway, we’re joined by James Short, CEO of Celadon Pharmaceuticals. We dive into the company’s exciting news of securing a five-year sales contract worth up to £10.5 million for the supply of medicinal cannabis. James shares details about the contract’s minimum order volumes, the strategic collaboration with Valeos Pharma A/S, and how these developments position Celadon to expand its UK and European operations. With an order book potential of £40.7 million, the future looks promising for Celadon. Tune in to hear more about the company’s plans and what’s next for the medicinal cannabis industry!

The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.